NASDAQ: COGT

Cogent Biosciences Inc Stock Forecast, Predictions & Price Target

The consensus among 4 Wall Street analysts covering (NASDAQ: COGT) stock is to Strong Buy COGT stock.

Out of 4 analysts, 2 (50%) are recommending COGT as a Strong Buy, 2 (50%) are recommending COGT as a Buy, 0 (0%) are recommending COGT as a Hold, 0 (0%) are recommending COGT as a Sell, and 0 (0%) are recommending COGT as a Strong Sell.

If you're new to stock investing, here's how to buy Cogent Biosciences stock.

(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.

Cogent Biosciences's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast COGT's revenue for 2025 to be $2,631,095,807, with the lowest COGT revenue forecast at $1,278,083,855, and the highest COGT revenue forecast at $3,984,107,759. On average, 4 Wall Street analysts forecast COGT's revenue for 2026 to be $10,127,092,067, with the lowest COGT revenue forecast at $1,904,207,145, and the highest COGT revenue forecast at $16,133,655,565.

In 2027, COGT is forecast to generate $31,161,475,773 in revenue, with the lowest revenue forecast at $11,914,428,607 and the highest revenue forecast at $56,316,646,421.

According to 4 Wall Street analysts that have issued a 1 year COGT price target, the average COGT price target is $24.25, with the highest COGT stock price forecast at $27.00 and the lowest COGT stock price forecast at $22.00.

On average, Wall Street analysts predict that Cogent Biosciences's share price could reach $24.25 by Nov 27, 2024. The average Cogent Biosciences stock price prediction forecasts a potential upside of 243.97% from the current COGT share price of $7.05.

(NASDAQ: COGT) forecast ROE is N/A, which is considered weak.